Monthly Archives: March 2015

Ocata Therapeutics Successfully Completes Dosing in Phase 1/2 RPE Studies

Here’s a cogent, intelligent, and rational comment to the news below:
3458qu9fqu4589q3u-!!!!! OMG I DON’T EVEN. O.o.
This moment has been brought to you by the Department of Medical Miracles to Come. 🙂
THIS IS WHAT WE’VE BEEN WAITING FOR!!! It’s the OFFICIAL announcement! Ocata can now start the second trial! They have pivotal trial status from the European Medicines Agency! This means that they can start marketing the drug after the next trial is over! It would be the FIRST stem cell based drug approved since 1956! Yes, I really DO think that we need all of these exclamation points!!!

Capslock? What capslock? 😉

Ahem. Anyway, check it out. 🙂
Ocata’s Press Release on the Completion of Phase I/II of SMD Trials

The UC-Davis Ethics Conference, Part 7: The Mystery Man Revealed!

At the end of Part Six, we were finally about to learn the identity of the mystery man who’d spoken up at Tim Caulfield’s lecture the night before… and in Part Seven, we finally do…
+++
Continue reading

UC-Davis Stem Cell Ethics Conference: Part Six, The Amazing Paul Knoepfler

Hey, all! Yep, today our story continues. When we left off at the end of Part 5, UC-Davis scientist and stem cell blogger extraordinaire, Paul Knoepfler, was about to take the stand to speak… and here he is. There’s also a teaser at the end for a BIG surprise tomorrow, in Part Seven…
+++
“The FDA’s mission is to assist safety and efficacy and speed innovations,” Paul Knoepfler said in a soft voice. “The issue is getting the two to mix. Believe me, I do realize that a lot of people see this as an issue. But the thing is, no other regulatory body oversees stem cell medications in the U.S. And in the past, various drug mistakes have hurt or killed people. There’s no way around that. Thalidomide is a good example.”

Oh, please, please don’t show any slides of deformed babies, I silently prayed.

Whether it was because he’d read my mind or not, none of those were shown. I knew what had happened in the late 1950’s with thalidomide, a drug originally used as a mild sedative and sleeping pill. It was also given to pregnant women to lessen morning sickness, with tragic, unforgivable results. But what I hadn’t known was that the FDA had not approved the drug in the US, despite considerable business pressures at the time. Thalidomide had been marketed and sold in the rest of the world, starting in Germany. It was one of the most widely prescribed drugs of any kind in that era. If I hadn’t already been listening intently—which I was, of course, because this was Paul Knoepfler—then that was a fact that would have made me sit up and pay attention.
Continue reading

The Latest Info About Stem Cells and Alzheimer’s

A reviewer on Amazon asked me if I knew anything about new Alzheimer’s treatments in development, which led to this! I don’t think Amazon is letting through links in reviews or comments anymore, so this is definitely the best way to get it.

Here’s a great, brand-new scholarly article about the current state of stem cell therapies being developed for Alzheimer’s (personally, as y’all probably know by now, I think that’s where the cure will come from.)

“Stem cell therapy for Alzheimer’s disease and related disorders: current status and future perspectives.”

The best part is that the full article is available free on Pubmed Central. Here’s the link for that:

Absolutely free full text PDF!

Another thing I know of is some new work with identifying more information about a gene that carries risk for developing Alzheimer’s. The stem cell link is that induced pluripotent stem cells are being used in the process (which is the best use for them at the present time, I think. IMHO, they’re so not ready for clinical application.)

Elucidating Molecular Phenotypes Caused by the SORL1 Alzheimer’s Disease Genetic Risk Factor Using Human Induced Pluripotent Stem Cells.

So take a look at those (especially the first one), and I’ll have Day Six of the UC-Davis conference coming up very soon. 🙂

How to get the full text of that article about stem cell-based vision treatments

If you don’t have academic access to full-text articles in scientific journals, you generally have a very hard time getting them. Believe me… I know what that’s like. In fact, the saga of my odyssey to OHSU to try to get a journal article is coming up in the posts! But if you want to read the entire article that was mentioned a couple of posts down (and you really should,) a science professional has very graciously stepped up and offered to send the PDF to all requesters. So here’s what you do. Copy and paste:

iarons(at)erols.com

and replace the at with @; you know the drill. We’re trying to evade the evil spambots. Request the article:

Stem cell treatment of degenerative eye disease.

Don’t forget to thank Irv! 🙂

UC-Davis Stem Cell Ethics Conference: Part Five

Hey all,

So… we’re done with the raw notes for now, and we’re back to the writing! Believe me, you do NOT want to miss the info in today’s installment. If you’ve ever wondered whether or not you should keep your investments in a certain biotech company, for instance… the answer’s here. Enjoy!
+++
PART FIVE.
Continue reading

UC-Davis Stem Cell Ethics Conference, Part 4

So here it is, y’all– the fourth installment! This is the LAST “notes from raw slides” section, SO please keep hanging in there… because this is important. Reading these notes may not the most entertaining activity on earth; believe me, I know. (I had to transcribe them from horrible blurry pics!) But there’s a lot to be gleaned here. If you’ve ever wondered how a drug goes from concept to market, this is one you want to read. (Just go down to Slide 9.)

***
THE NEXT SPEAKER AT THE UC-DAVIS CONFERENCE…
Continue reading

An important new study on stem cells and vision replacement.

If you haven’t seen this one already, you do NOT want to miss it!!
Stem cell treatment of degenerative eye disease.

A really great, broad overview of what’s going on with the usefulness of different types of stem cells and vision right now. It’s even BETTER if you have institutional access and can read the entire article… but either way, don’t miss this one.

UC-Davis Stem Cell Ethics Conference, Part 3

At the end of Part 2, the opening night of the conference had just ended. We pick up the next day with the main speakers. More secrets of illegal stem clinics are revealed…
+++

At the main conference the next day, I searched through tired-looking pastries on the side table, keeping a close eye on the other attendees. Virtually everyone seemed to be an academic. Paul Knoepfler was like an adorable teddy bear, huggable and self-effacing, all but blushing when I asked for a picture and an autograph.

There was the bouncy-ball-man again. He was leaning forward and talking loudly to a woman whose name tag proclaimed she was Alison Sorkin, a UC-Davis professor of bioscience. I tried to read his name tag, but he was turned away from me. He certainly did sound enthusiastic. A tall man leaned partly against a pillar, listening with a faint smile on his face, the corners of his eyes gently creased. I guessed his age at around sixty-five; he had the healthy, fit look of a man who had spent his life doing rigorous physical work. But his eyes were very sad. A woman stood listening to them all, a few feet away, her dark hair cut in a pixie shape around her soft face. Her hands nervously plucked at each other, and she seemed to be taking a series of short deep breaths, as if building a sentence that never quite got all the way to her lips. I wondered who all of them were. The identity of the woman mystified me just as much as the bouncy-ball man. I would be willing to bet that she wasn’t an academic either.

We all took our seats (and very uncomfortable ones they were, too,) and the presentations began.
Continue reading

The UC-Davis Stem Cell Ethics Conference, The Whole Story: Part Two

At the end of part one, Tim Caulfield, keynote speaker at the conference, was addressing the problem of illegal stem cell clinics worldwide…

+++

Tim Caulfield looked up. “So what’s the harm?” he asked.

I wasn’t sure if anyone in the audience was supposed to answer the question, but I did not have a good feeling about whatever was coming next.
Continue reading